Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.

Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, Garraway LA.

Nature. 2013 Dec 5;504(7478):138-42. doi: 10.1038/nature12688. Epub 2013 Nov 3.

PMID:
24185007
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA.

Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627. Epub 2010 Nov 24.

PMID:
21107320
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.

Jalili A, Wagner C, Pashenkov M, Pathria G, Mertz KD, Widlund HR, Lupien M, Brunet JP, Golub TR, Stingl G, Fisher DE, Ramaswamy S, Wagner SN.

J Natl Cancer Inst. 2012 Nov 7;104(21):1673-9. doi: 10.1093/jnci/djs373. Epub 2012 Sep 20.

PMID:
22997239
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS.

Nature. 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24.

PMID:
21107323
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R.

Nature. 2014 Apr 3;508(7494):118-22. doi: 10.1038/nature13121. Epub 2014 Mar 26.

PMID:
24670642
[PubMed - indexed for MEDLINE]
6.

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB.

Nature. 2011 Nov 23;480(7377):387-90. doi: 10.1038/nature10662.

PMID:
22113612
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.

Ambrosini G, Pratilas CA, Qin LX, Tadi M, Surriga O, Carvajal RD, Schwartz GK.

Clin Cancer Res. 2012 Jul 1;18(13):3552-61. doi: 10.1158/1078-0432.CCR-11-3086. Epub 2012 May 1.

PMID:
22550165
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.

Wang AX, Qi XY.

IUBMB Life. 2013 Sep;65(9):748-58. doi: 10.1002/iub.1193. Epub 2013 Jul 29. Review.

PMID:
23893853
[PubMed - indexed for MEDLINE]
9.

Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.

Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, Buchanan S, Henry JR, Starling JJ, Peng SB.

J Biol Chem. 2012 Aug 10;287(33):28087-98. doi: 10.1074/jbc.M112.377218. Epub 2012 Jun 22.

PMID:
22730329
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.

Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM.

Mol Cancer Ther. 2012 Apr;11(4):909-20. doi: 10.1158/1535-7163.MCT-11-0989. Epub 2012 Mar 2.

PMID:
22389471
[PubMed - indexed for MEDLINE]
Free Article
11.

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.

Shi H, Kong X, Ribas A, Lo RS.

Cancer Res. 2011 Aug 1;71(15):5067-74. doi: 10.1158/0008-5472.CAN-11-0140.

PMID:
21803746
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.

Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H.

J Invest Dermatol. 2012 Jul;132(7):1850-9. doi: 10.1038/jid.2012.63. Epub 2012 Mar 22. Erratum in: J Invest Dermatol. 2013 Oct;133(10):2493.

PMID:
22437314
[PubMed - indexed for MEDLINE]
Free Article
13.

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N.

Nature. 2010 Mar 18;464(7287):427-30. doi: 10.1038/nature08902.

PMID:
20179705
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.

Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA.

Sci Signal. 2010 Nov 23;3(149):ra84. doi: 10.1126/scisignal.2001148.

PMID:
21098728
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.

Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P, Zhang XD.

Clin Cancer Res. 2011 Feb 15;17(4):721-30. doi: 10.1158/1078-0432.CCR-10-2225. Epub 2010 Nov 18.

PMID:
21088259
[PubMed - indexed for MEDLINE]
Free Article
16.

Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression.

Kono M, Dunn IS, Durda PJ, Butera D, Rose LB, Haggerty TJ, Benson EM, Kurnick JT.

Mol Cancer Res. 2006 Oct;4(10):779-92.

PMID:
17050671
[PubMed - indexed for MEDLINE]
Free Article
17.

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma.

Hu W, Jin L, Jiang CC, Long GV, Scolyer RA, Wu Q, Zhang XD, Mei Y, Wu M.

Cell Death Dis. 2013 Nov 7;4:e914. doi: 10.1038/cddis.2013.441.

PMID:
24201813
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N.

Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14903-8. doi: 10.1073/pnas.1008990107. Epub 2010 Jul 28.

PMID:
20668238
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies.

Fattore L, Marra E, Pisanu ME, Noto A, de Vitis C, Belleudi F, Aurisicchio L, Mancini R, Torrisi MR, Ascierto PA, Ciliberto G.

J Transl Med. 2013 Jul 27;11:180. doi: 10.1186/1479-5876-11-180.

PMID:
23890105
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman LS, Belvin M.

Cancer Res. 2009 Apr 1;69(7):3042-51. doi: 10.1158/0008-5472.CAN-08-3563. Epub 2009 Mar 10.

PMID:
19276360
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk